Skip to main content

Main menu

  • Home
  • About the Journal
    • General Information
    • Scope
    • Editorial Board
    • Benefits of Publishing
    • Impact & Metrics
    • Advertising/Sponsorship
    • About the Biochemical Society
  • Current Issue
  • For Authors
    • Submit Your Paper
    • Submission Guidelines
    • Editorial Policy
    • Open Access Policy
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • For Librarians
    • Open Access Policy
    • Terms and Conditions
      • Biochemical Journal- Terms and Conditions of Usage
      • Bioscience Reports- Terms and Conditions of Usage
  • For Readers
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • Collections
  • Help
    • Technical Support
    • Contact Us
  • Other Publications
    • Biochemical Journal
    • Clinical Science
    • Bioscience Reports
    • Neuronal Signaling
    • Biochemical Society Transactions
    • Essays in Biochemistry
    • Emerging Topics in Life Sciences
    • Biochemical Society Symposia
    • Cell Signalling Biology
    • Glossary of Biochemistry and Molecular Biology
    • The Biochemist
    • Biochemical Society

User menu

  • Log-in
  • Subscribe
  • Contact Us
  • Log out

Search

  • Advanced search
  • Other Publications
    • Biochemical Journal
    • Clinical Science
    • Bioscience Reports
    • Neuronal Signaling
    • Biochemical Society Transactions
    • Essays in Biochemistry
    • Emerging Topics in Life Sciences
    • Biochemical Society Symposia
    • Cell Signalling Biology
    • Glossary of Biochemistry and Molecular Biology
    • The Biochemist
    • Biochemical Society

Log-in

Sign-up for alerts  
  • My Cart
Bioscience Reports
Browse Archive
Advanced Search
  • Home
  • About the Journal
    • General Information
    • Scope
    • Editorial Board
    • Benefits of Publishing
    • Impact & Metrics
    • Advertising/Sponsorship
    • About the Biochemical Society
  • Current Issue
  • For Authors
    • Submit Your Paper
    • Submission Guidelines
    • Editorial Policy
    • Open Access Policy
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • For Librarians
    • Open Access Policy
    • Terms and Conditions
  • For Readers
    • Rights and Permissions
    • Biochemical Society Member Benefits
  • Collections
  • Help
    • Technical Support
    • Contact Us

Research Article

Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP

Peng Ruan, Zezhang Tao, Aili Tan
Bioscience Reports Jan 25, 2018, 38 (1) BSR20171027; DOI: 10.1042/BSR20171027
Peng Ruan
Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
Zezhang Tao
Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
  • For correspondence: yfzhao20110603@163.com
Aili Tan
Department of Obstetrics & Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • View author's works on this site
  • Article
  • Figures
  • Info & Metrics
  • PDF
Loading

Abstract

The study aimed at investigating the effects of miR-30a-5p on the biological functions of oral cancer cells and figuring out the potential mechanism. We first verified the low expression of miR-30a-5p and high expression of FAP (Homo sapiens fibroblast activation protein α) in oral cancerous tissues and their negative correlation. Then, the target relationship between miR-30a-5p and FAP was validated by dual luciferase reporter assay and biotin-coupled miRNA pulldown assay. After transfection in Tca-8113 cells and SCC-15 cells, MTT, colony formation, Transwell, and wound healing assays were performed to investigate how miR-30a-5p and FAP adjusted propagation, invasiveness, and migration, respectively. Mounting evidence supported that miR-30a-5p directly targetted FAP and suppressed its expression in oral cavity cancer cells (OSCCs). By suppressing FAP expression, miR-30a-5p significantly inhibited cell propagation, migration, and invasion. Therefore, miR-30a-5p might be a new therapeutic target for oral cancer treatment.

  • FAP
  • miR-30a-5p
  • Oral cancer

Introduction

Oral cavity carcinoma was a common malignancy amongst patients with head and neck carcinoma [1]. Researchers found that alcohol and cigarettes consumption as well as human papilloma virus infection, diet, and genetic factors could possibly induce abnormal gene expression, thus leading to the occurrence and development of oral cancers [2,3]. Differing from other cancers like breast, lung, stomach, and kidney cancer, which were susceptible to neoplasm metastasis, local progression, and lymph node involvement of oral cancer was limited [4]. Presently, the primary treatments for oral cancer consisted of surgery, chemotherapy, drug therapy, and radiotherapy [5]. These treatments could improve the prognosis, but late discovery and distant metastases contributed to the relatively high morbidity and mortality rates in oral cancer patients [6–8]. Therefore, it was vital to improve the accuracy of early diagnosis of oral cancer and to find potential factors that may serve as targets for drug therapy.

Highly conserved amongst various eucaryon, miRNA acted as regulators of gene expression by binding to or repressing mRNAs during transcriptional or translational process [9]. Aberrant miRNA expression has been regarded as common features of cancer development [10]. According to the study of Liborio-Kimura et al. [11], miR-494 reduced the proliferation of oral cancer cells by repressing the expression of HOXA10. Here, we focus on the functional analysis of miR-30a-5p. Altered expression of miR-30a-5p has been reported in colon cancer, glioma, and hepatocellular cancer [12–14]. Through targetting DTL (denticle-less protein homolog), miR-30a-5p suppressed the tumor growth in colon carcinoma [15]. In glioma cells, miR-30a-5p negative regulated SEPT7 and promoted cell proliferation and invasion [16]. However, mechanism of miR-30a-5p in oral cancer had never been validated yet.

Fibroblast activation protein (FAP) was a homodimer integral membrane gelatinase belonging to the serine protease family. Its aberrant expression had been suggested as a carcinogenic marker [6,15–17]. By dissociating the growth factors with matrix proteins, FAP could promote the tumor microvascular generation and the growth of tumor cells, and played an important role in the invasion and metastasis of tumors [18]. Gong et al. [19] found that miR-21 induced the expression of FAP and promoted the malignant progression of breast phyllodes tumors. Consistently, Wang et al. [6] found that the down-regulation of FAP in oral cancer could inhibit cell propagation by activating phosphatase and tensin homology deleted on chromosome 10/phosphoinositide 3-kinase/AKT (PTEN/P13K/AKT) and Ras-extracellular signal regulated kinase (Ras-ERK) signaling pathways. Unfortunately, there was no study on how miRNAs regulated the expression of FAP in oral cancer cells.

Up to now, few researches about miRNAs’ abnormity in oral cancer had been done and the current study focussed on miR-30a-5p/FAP function on the viability, proliferation, migration, and invasiveness of oral cancer cells.

Materials and methods

Clinical specimens

Sixty six oral cancer tissues and 25 adjacent normal tissues (at least 2–3 cm from the tumor margin, verified to be free of tumor) were obtained from surgical resection. Inclusion criteria were applied as described in a recent study [20]. In brief, patients were diagnosed with cancer of the oral cavity but did not receive radiotherapy and chemotherapy before. Written consents were confirmed. Two cohorts of human oral cancer collected at Renmin Hospital of Wuhan University in the year of 2015. All clinical specimens preserved in liquid nitrogen until RNA extraction. The present study was approved by Renmin Hospital of Wuhan University and all participants signed an informed consent agreement. All clinical information for human oral cancer tissues was presented in Table 1.

View this table:
  • View inline
  • View popup
Table 1 Clinicopathological Features of oral cancer tissues

Cell culture

Normal human oral epithelial cells (NHOECs) were obtained via primary culture: resected oral mucosa was washed with PBS, digested in Dispase II at 4°C for 24 h, and then digested in trypsin. The cells were subsequently inoculated and cultured at a density of 1 × 106/30000 mm2. Tca-8113 and HEK-293T were purchased from Bena Culture Collection, and SCC-15, SCC-25, SCC-4 from ATCC. These cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) which contained 10% FBS, 100 U/ml streptomycin, and 100 U/ml penicillin under the conditions of 37°C in 5% CO2 and 95% atmospheric humidity.

Cell transfection

FAP siRNA, miR-30a-5p mimics, mimics control (mirVana™ miRNA Mimic, negative control #1, catalog (Cat): 4464058), miR-30a-5p inhibitor and inhibitor control (Ambion® Anti-miR™ miRNA Inhibitor Negative Control #1, Cat: AM17010) were all synthesized by Thermo Fisher Scientific, U.S.A. All sequences’ information is provided in Table 2. PcDNA3.1-EGFP vector was purchased from Genechem Co., Ltd (Shanghai, China). Lipofectamine™ 2000 (Invitrogen, U.S.A.) was used to transfect RNA and vector.

View this table:
  • View inline
  • View popup
Table 2 Sequences for qRT-PCR, PCR, siRNAs, mimics, inhibitors

RNA extraction and RT-qPCR

According to the instructions of reverse transcription (RT) kit (Promega, Madison, WI, U.S.A.), we extracted total RNA from frozen clinical specimens with TRIzol reagent and reversed RNA into cDNA. Chain amplification was then carried out based on qPCR kit (Invitrogen, Carlsbad, CA, U.S.A.). U6 and GAPDH were the used as loading control. The primers (Sangon, Shanghai, China) sequences were displayed in Table 2.

Western blot analysis

The total protein was extracted from transfected cells and the concentration was subsequently quantitated using BCA protein quantitative method. After SDS/PAGE protein electrophoresis, proteins were transferred on to a PVDF membrane and blocked with 5% skim milk for 2 h. Primary antibodies of FAP and GAPDH (Abcam, Cambridge, MA, U.S.A.) were incubated overnight at 4°C. Then, HPR-conjugated secondary antibodies were incubated for 1 h. The film was then developed using ECL.

Dual luciferase reporter gene assay

FAP 3′-UTR wild-type and mutant were amplified with FAP cDNA. The sequences were amplified using primers provided in Table 2. Then pGL3 plasmids (both wild-type and mutated) were inserted into the UTRs. Then, the recombined 3′-UTR pGL3 plasmids were transiently transfected into HEK-293T cells together with miR-30a-5p mimics or mimics control by Lipofectamine™ 2000 according to the manufacturer’s instructions.

Biotin-coupled miRNA capture

The biotin-coupled miRNA pulldown was performed as previously described [21]. In brief, we labeled miR-30a-5p mimics and mimics control with biotin at the 3′ end and then transient transfected the biotin-labeled sequence into HEK-293T cells which stably expressed FAP (stably transfection of pCDNA3.1-FAP) at a final concentration of 30 nM for 24 h. Total RNA was separated and incubated with streptavidin beads (Life Technology) to capture the biotin-coupled miRNA mimics. The abundance of FAP mRNA in bound fractions was evaluated by RT-qPCR.

MTT assay

Transfected cells in the logarithmic growth phase were seeded in a 96-well plate with a density of 5 × 103/ well. MTT (10 mg/ml) was added to each well and cultured for another 4 h. Then 100 µl DMSO was added to each well. Optical absorbance at a wavelength of 450 nm was recorded.

Colony formation assay

Six groups of cells were inoculated on to 60-mm plates with a density of 600 per well. After being incubated for 13 days, cells were washed with PBS, fixed with 10% formaldehyde for 15 min, and stained for 30 min with Crystal Violet. Colony number for each group was observed and recorded under a microscope.

Wound healing assay

Cells were incubated in a six-well plate at a density of 2 × 105 per well. After the cells reached a confluence of 80%, we used a 100-µl sterile micropipette to scratch a straight line on the surface of each well. Cells were first washed with PBS, and then incubated in Dulbecco’s modified Eagle’s medium (DMEM) that contained 2% FBS. The plate was photographed at 0 and 24 h and migration rate was measured with an inverted microscope.

Invasion assay

Transwell chambers were covered with Matrigel (20 μl, 0.5 g/l) and placed on a 24-well plate. Lower chambers were added with RPMI-1640 that contained 10% FBS, while upper chambers were filled with 200 μl cell suspension. After being incubated for 36 h, invading cells were fixed in 4% paraformaldehyde and stained with 0.1% Crystal Violet. Twelve randomly selected fields were photographed and cells were counted under a microscope.

Statistical analysis

GraphPad Prism 6.0 was used to conduct statistical analysis and plotting. All the data were presented as mean ± S.D. Differences between the two groups were analyzed using Mann–Whitney U test. Comparisons amongst groups were performed with ANOVA. P<0.01 was considered to have significant statistical difference. MTT and invasion assay used three wells in each group and all were performed in triplicate for accuracy.

Results

MiR-30a-5p was lowly expressed while FAP was highly expressed in oral cancer

To evaluate the expression level of miR-30a-5p and FAP in oral cancer patients, we collected 66 oral cancer tissues and 25 adjacent non-cancerous tissues. On an average, miR-30a-5p expression in cancer tissues was 0.35-times as that of the adjacent tissues, while FAP mRNA expression in cancer tissues was 3.3-times higher than adjacent tissues (P<0.05, Figure 1A,B). Besides, miR-30a-5p and FAP were negatively correlated in adjacent tissues as well as in oral squamous carcinoma cells (OSCCs) as shown in Figure 1C,D (P<0.05). Western blot confirmed that FAP was highly expressed in cancer tissues (Figure 1E). Besides, FAP was also highly expressed in different OSCC cell lines Tca-8113, SCC-4, SCC-15, SCC-25 compared with normal cell line NHOEC (Figure 1F). We further detected RNA expression of miR-30a-5p in different cell lines, amongst which Tca-8113 and SCC-15 cells showed lower expression (Figure 1G); and mRNA level of FAP in different cell lines was most highly up-regulated in Tca-8113 and SCC-15 cells (Figure 1H).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 MiR-30a-5p was lowly expressed while FAP was highly expressed in oral cancer

(A) MiR-30a-5p mRNA was significantly lower in OSCC cells than normal ones. (B) FAP mRNA was significantly lower in OSCC cells than normal ones. (C) MiR-30a-5p was negatively correlated with FAP in normal cells. (D) MiR-30a-5p was negatively correlated with FAP in OSCC cells. (E) FAP was highly expressed in OSCC cells by Western blot. (F) FAP was highly expressed in all OSCC cell lines including Tca-8113, SCC-4, SCC-15, and SCC-25. (G) MiR-30a-5p was lowly expressed in all OSCC cell lines and most significant changes were detected in Tca-8113 and SCC-15 group. (H) FAP was lowly expressed in all OSCC cell lines and most significant changes were detected in Tca-8113 and SCC-15 group; **, P<0.01, represented significant differences compared with NHOEC group.

MiR-30a-5p directly targetted FAP and suppressed its expression

TargetScan (http://www.targetscan.org/) predicted the targetting sites for miR-30a-5p and FAP 3′-UTR, and HEK-293T cells, which served as a vector, were co-transfected with pGL-3FAP-WT, pGL-3FAP-MUT, miR-30a-5p mimics, and mimics control. The relative luciferase activity of pGL-3-FAP-WT group was significantly lower than pGL-3-FAP-MUT group, indicting a direct target relationship between miR-30a-5p and FAP (P<0.01, Figure 2A). In addition, HEK-293T cells stably expressing FAP after FAP cDNA transfection were transiently transfected with biotinylated miR-30a-5p (Bi-miR-30a-5p) or biotinylated non-specific miRNA (Bi-NC). RT-qPCR analysis of FAP mRNA level indicated FAP mRNA was 3.5-times higher than that in Bi-NC group (normalized as 1) (P<0.05, Figure 2B), further verifying the target relationship. Cells were divided into eight groups: control (no treatment), NC (Lipofectamine™ 2000 treatment), mimics (miR-30a-5p mimics), inhibitor (miR-30a-5p inhibitor), FAP (pcDNA3.1-FAP), siFAP (FAP siRNA), mimics + siFAP (miR-30a-5p mimics and FAP siRNA), and mimics + FAP (miR-30a-5p mimics and pcDNA3.1-FAP), each group was compared with the control (normalized as 1). At 48 h after transfection, miR-30a-5p mRNA expressions drastically increased in miR-30a-5p mimics group, miR-30a-5p mimics + siFAP group and miR-30a-5p mimics + FAP group (all P<0.01), while it decreased in miR-30a-5p inhibitor group (P<0.05). FAP mRNA expressions significantly increased in miR-30a-5p inhibitor group and FAP group while decreased in mimics group, siFAP group, and miR-30a-5p mimics + siFAP group (all P<0.01, Figure 2C,D). Protein expression changes in miR-30a-5p mimics + siFAP and miR-30a-5p mimics + FAP group also confirmed that FAP siRNA or cDNA had no effect on miR-30a-5p expression but conversely miR-30a-5p could decrease FAP expression (Figure 2E).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 MiR-30a-5p directly targetted FAP and suppressed its expression

(A) TargetScan predicted the target site of FAP at 173–180. Luciferase activity confirmed the direct target relationship between miR-30a-5p and FAP. (B) FAP mRNA expression was significantly higher in Bi-miR-30a-5p group than in Bi-NC group after biotin-coupled miRNA sedimentation by qRT-PCR. (C) MiR-30a-5p mRNA expression increased in miR-30a-5p mimics, miR-30a-5p mimics + siFAP, and miR-30a-5p mimics + FAP groups while decreased in miR-30a-5p inhibitor group. (D) FAP mRNA expression decreased in miR-30a-5p mimics, siFAP, and miR-30a-5p mimics + FAP groups while increased in miR-30a-5p inhibitor group and FAP groups. (E) FAP protein expression decreased in miR-30a-5p mimics, siFAP, and miR-30a-5p mimics + FAP groups while increased in miR-30a-5p inhibitor group and FAP groups; **, P<0.01, represented significant differences compared with control group.

MiR-30a-5p suppressed the cell proliferation of oral cancer cells via down-regulating FAP

MTT assay revealed that miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA could significantly reduce the cell viability of both Tca-8113 and SCC-15 cells, but miR-30a-5p inhibitor and FAP could both increase the cell viability. Therefore, FAP may accelerate cell proliferation which could reversely be reduced by miR-30a-5p (Figure 3A). Clone formation assay validated the same conclusion considering smaller colony number in miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups, and larger colony number in miR-30a-5p inhibitor and FAP groups (Figure 3B).

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3 MiR-30a-5p suppressed the cell proliferation of oral cancer cells via down-regulating FAP

(A) MiR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA could significantly reduce the cell viability of both Tca-8113 and SCC-15 cells, but miR-30a-5p inhibitor and FAP could both increase the cell viability. (B) Colony number was smaller in miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups but larger in miR-30a-5p inhibitor and FAP groups; **, P<0.01, represented significant differences compared with control group.

MiR-30a-5p suppressed the migration and invasion of oral cancer cells via down-regulating FAP

Smaller wound healing area indicated stronger migration ability, therefore, miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups shared weaker migration ability, while miR-30a-5p inhibitor and FAP group shared stronger invasion ability (all P<0.01, Figure 4A). Invasion ability was valued by invading cells in Tca-8113 and SCC-15 cell lines. As shown in Figure 4B, miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups showed weaker invasion ability, while miR-30a-5p inhibitor and FAP groups displayed stronger invasion ability.

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4 MiR-30a-5p suppressed the migration and invasion of oral cancer cells via down-regulating FAP

(A) MiR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups shared weaker migration ability, while miR-30a-5p inhibitor and FAP group shared stronger invasion ability. (B) miR-30a-5p mimics, FAP siRNA, miR-30a-5p mimics + FAP siRNA groups showed weaker invasion ability, while miR-30a-5p inhibitor and FAP groups displayed stronger invasion ability; **, P<0.01, represented significant differences compared with control group.

Discussion

In the present study, we confirmed that miR-30a-5p directly targetted FAP and down-regulated FAP expression in OSCC cell lines. Furthermore, miR-30a-5p suppressed the proliferation, migration, and invasion by inhibiting FAP in functional experiments.

MiR-30a family, namely miR-30a-3p and miR-30a-5p, plays a tumor-suppressive role in various cancers, including breast cancer, hepatocellular carcinoma, lung cancer, glioblastoma, colon cancer, and prostatic cancer [13,14,22–25]. Besides, miR-30a-5p has been reported to function in prediction and diagnosis for diverse cancers, such as renal cell carcinoma, low histological grade chondrosarcoma, giant cell tumor, breast cancer, prostate cancer, and lung cancer [13,26–31]. Some researchers have revealed its negative association with tumor progression. For example, Tang et al. [23] discovered that miR-30a-5p was lowly expressed in lung cancer and negatively associated with tumor size, lymphatic metastasis, histological classification, clinical TNM stage, pathological progression, and overall survival rate, as a tumor inhibitor. In the present study, miR-30a-5p was substantially down-regulated in OSCC tissues, suggesting that it might be a tumor suppressor during OSCC progression.

The relationship between miR-30a-5p and target genes has been reported previously. For instance, Yu et al. [32] reported that autophagy-related gene (ATG) could be directly regulated by miR-30a-5p in the chronic myelogenous leukemia cells. Ouzounova et al. [33] found that overexpression of miR-30a-5p significantly down-regulated AVEN (apoptosis and caspase activation inhibitor), which partly contributed to the reduction in breast cancer progression. Chen et al. [34] found that miR-30a-5p inhibited cell migration and invasion by decreasing the expression of vimentin expression in breast cancer. Increasing evidence indicated that astrocyte elevated gene-1 (AEG-1) could be a potential target gene of miR-30a-5p in breast cancer, lung cancer, and hepatocellular carcinoma [35–37]. We herein discovered that miR-30a-5p could directly bind to FAP in OSCCs and activate a series of cell activities including propagation, migration, and invasion.

Previous researchers found that FAP was selectively up-regulated on the surface of cancer-related fibroblasts adjacent to epithelial cancers, such as colorectal, pancreatic, breast, and lung cancers [38–40]. We also found that FAP was significantly up-regulated in OSCCs and tissues, indicating that FAP might be an oncogene for OSCC pathogenesis. MiR-30a-5p could partially inhibit FAP expression. FAP knockdown hindered the viability, proliferation, migration, and invasiveness in OSCC cells. The present study then verified that miR-30a-5p could inhibit tumorigenesis by directly regulating FAP.

In spite of all findings, there exist some limitations in the present study. Further experiments to confirm the function of miR-30a-5p/FAP in vivo were omitted due to lack of time. The underlying mechanism of the inhibition still remains to be investigated. Therefore, more discussion could be proceeded for a thorough understanding of miR-30a-5p/FAP mechanism in oral cancers.

To sum up, the present study confirmed that miR-30a-5p directly targetted FAP and inhibited cell viability, proliferation, migration, invasiveness of OSCC cells, revealing miR-30a-5p as a suppressor in OSCC tumorigenesis and progression.

Ethics approval and consent to participate

All procedures were in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Renmin Hospital of Wuhan University. All patients who participated have signed consents for the present study.

Consent for publication

All the patients who participated have signed consent forms for publication in the present study.

Competing interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [grant number 81372880].

Author contribution

P.R. designed and drafted this research. P.R. and A.T. analyzed and interpreted the patients data. P.R., A.T., and Z.T. conducted statistical analysis. Z.T. critically revised the manuscript. All the authors read and approved the final manuscript.

Abbreviations: Bi-NC, biotinylated non-specific miRNA; Cat, catalog; FAP, fibroblast activation protein; NHOEC, normal human oral epithelial cell; qPCR, quantitative polymerase chain reaction; Ras-ERK, Ras-extracellular signal regulated kinase; RPMI, Roswell Park Memorial Institute-1640; RT, reverse transcription

  • © 2018 The Author(s).
http://creativecommons.org/licenses/by/4.0/

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).

References

  1. ↵
    1. Marocchio L.S.,
    2. Lima J.,
    3. Sperandio F.F.,
    4. Correa L.,
    5. de Sousa S.O.
    (2010) Oral squamous cell carcinoma: an analysis of 1,564 cases showing advances in early detection. J. Oral Sci. 52, 267–273
    OpenUrlPubMed
  2. ↵
    1. Chi A.C.,
    2. Day T.A.,
    3. Neville B.W.
    (2015) Oral cavity and oropharyngeal squamous cell carcinoma–an update. CA Cancer J. Clin. 65, 401–421
    OpenUrlCrossRefPubMed
  3. ↵
    1. Albuquerque R.,
    2. Lopez-Lopez J.,
    3. Mari-Roig A.,
    4. Jane-Salas E.,
    5. Rosello-Llabres X.,
    6. Santos J.R.
    (2011) Oral tongue squamous cell carcinoma (OTSCC): alcohol and tobacco consumption versus non-consumption. A study in a Portuguese population. Braz. Dent. J. 22, 517–521
    OpenUrlPubMed
  4. ↵
    1. Garavello W.,
    2. Ciardo A.,
    3. Spreafico R.,
    4. Gaini R.M.
    (2006) Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 132, 762–766
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Eid A.,
    2. Li S.,
    3. Garza R.,
    4. Wong M.E.
    (2014) Chemotherapy for oral and maxillofacial tumors: an update. Oral Maxillofac. Surg. Clin. North Am. 26, 163–169
    OpenUrl
  6. ↵
    1. Wang H.,
    2. Wu Q.,
    3. Liu Z.,
    4. Luo X.,
    5. Fan Y.,
    6. Liu Y.,
    (2014) Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 5, e1155
    OpenUrlCrossRefPubMed
    1. Leon X.,
    2. Quer M.,
    3. Diez S.,
    4. Orus C.,
    5. Lopez-Pousa A.,
    6. Burgues J.
    (1999) Second neoplasm in patients with head and neck cancer. Head Neck 21, 204–210
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Bhatia R.,
    2. Bahadur S.
    (1987) Distant metastasis in malignancies of the head and neck. J. Laryngol. Otol. 101, 925–928
    OpenUrlPubMedWeb of Science
  8. ↵
    1. Taganov K.D.,
    2. Boldin M.P.,
    3. Baltimore D.
    (2007) MicroRNAs and immunity: tiny players in a big field. Immunity 26, 133–137
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Ruan K.,
    2. Fang X.,
    3. Ouyang G.
    (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 285, 116–126
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Liborio-Kimura T.N.,
    2. Jung H.M.,
    3. Chan E.K.
    (2015) miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol. 51, 151–157
    OpenUrl
  11. ↵
    1. Baraniskin A.,
    2. Birkenkamp-Demtroder K.,
    3. Maghnouj A.,
    4. Zollner H.,
    5. Munding J.,
    6. Klein-Scory S.,
    (2012) MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 33, 732–739
    OpenUrlCrossRefPubMed
  12. ↵
    1. Jia Z.,
    2. Wang K.,
    3. Wang G.,
    4. Zhang A.,
    5. Pu P.
    (2013) MiR-30a-5p antisense oligonucleotide suppresses glioma cell growth by targeting SEPT7. PLoS ONE 8, e55008
    OpenUrlCrossRefPubMed
  13. ↵
    1. Dai H.,
    2. Kang B.,
    3. Zuo D.,
    4. Zuo G.
    (2014) Effect of miR-30a-5p on the proliferation, apoptosis, invasion and migration of SMCC-7721 human hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi 22, 915–920
    OpenUrl
  14. ↵
    1. Mori Y.,
    2. Kono K.,
    3. Matsumoto Y.,
    4. Fujii H.,
    5. Yamane T.,
    6. Mitsumata M.,
    (2004) The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology 67, 411–419
    OpenUrlCrossRefPubMed
  15. ↵
    1. Iwasa S.,
    2. Okada K.,
    3. Chen W.T.,
    4. Jin X.,
    5. Yamane T.,
    6. Ooi A.,
    (2005) Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett. 227, 229–236
    OpenUrlCrossRefPubMed
  16. ↵
    1. Shi M.,
    2. Yu D.H.,
    3. Chen Y.,
    4. Zhao C.Y.,
    5. Zhang J.,
    6. Liu Q.H.,
    (2012) Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 18, 840–846
    OpenUrlCrossRefPubMed
  17. ↵
    1. Busek P.,
    2. Balaziova E.,
    3. Matrasova I.,
    4. Hilser M.,
    5. Tomas R.,
    6. Syrucek M.,
    (2016) Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma. Tumour Biol., 37, 1–11
    OpenUrl
  18. ↵
    1. Gong C.,
    2. Nie Y.,
    3. Qu S.,
    4. Liao J.Y.,
    5. Cui X.,
    6. Yao H.,
    (2014) miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Cancer Res. 74, 4341–4352
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Fu G.,
    2. Somasundaram R.T.,
    3. Jessa F.,
    4. Srivastava G.,
    5. MacMillan C.,
    6. Witterick I.,
    (2016) ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy. Oncotarget 7, 17162–17181
    OpenUrl
  20. ↵
    1. Lal A.,
    2. Thomas M.P.,
    3. Altschuler G.,
    4. Navarro F.,
    5. O’Day E.,
    6. Li X.L.,
    (2011) Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 7, e1002363
    OpenUrlCrossRefPubMed
  21. ↵
    1. Rodriguez A.,
    2. Griffiths-Jones S.,
    3. Ashurst J.L.,
    4. Bradley A.
    (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res. 14, 1902–1910
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Tang R.,
    2. Liang L.,
    3. Luo D.,
    4. Feng Z.,
    5. Huang Q.,
    6. He R.,
    (2015) Downregulation of miR-30a is associated with poor prognosis in lung cancer. Med. Sci. Monit. 21, 2514–2520
    OpenUrl
    1. Kanazawa S.,
    2. Soucek L.,
    3. Evan G.,
    4. Okamoto T.,
    5. Peterlin B.M.
    (2003) c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 22, 5707–5711
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Ma Y.,
    2. Zhang P.,
    3. Yang J.,
    4. Liu Z.,
    5. Yang Z.,
    6. Qin H.
    (2012) Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int. J. Cancer 130, 2077–2087
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Zheng B.,
    2. Zhu H.,
    3. Gu D.,
    4. Pan X.,
    5. Qian L.,
    6. Xue B.,
    (2015) MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Biochem. Biophys. Res. Commun. 459, 234–239
    OpenUrlCrossRefPubMed
    1. Lu N.,
    2. Lin T.,
    3. Wang L.,
    4. Qi M.,
    5. Liu Z.,
    6. Dong H.,
    (2015) Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma. Tumour Biol. 36, 3843–3852
    OpenUrlCrossRefPubMed
    1. Katz B.,
    2. Reis S.T.,
    3. Viana N.I.,
    4. Morais D.R.,
    5. Moura C.M.,
    6. Dip N.,
    (2014) Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS ONE 9, e113700
    OpenUrlCrossRefPubMed
    1. Huang Q.,
    2. Jiang Z.,
    3. Meng T.,
    4. Yin H.,
    5. Wang J.,
    6. Wan W.,
    (2014) MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochem. Biophys. Res. Commun. 453, 160–165
    OpenUrl
    1. Perez-Rivas L.G.,
    2. Jerez J.M.,
    3. Carmona R.,
    4. de Luque V.,
    5. Vicioso L.,
    6. Claros M.G.,
    (2014) A microRNA signature associated with early recurrence in breast cancer. PLoS ONE 9, e91884
    OpenUrl
  25. ↵
    1. Zhang H.H.,
    2. Zhang Z.Y.,
    3. Che C.L.,
    4. Mei Y.F.,
    5. Shi Y.Z.
    (2013) Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines. Int. J. Clin. Exp. Pathol. 6, 1734–1746
    OpenUrlPubMed
  26. ↵
    1. Yu Y.,
    2. Cao L.,
    3. Yang L.,
    4. Kang R.,
    5. Lotze M.,
    6. Tang D.
    (2012) microRNA 30A promotes autophagy in response to cancer therapy. Autophagy 8, 853–855
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ouzounova M.,
    2. Vuong T.,
    3. Ancey P.B.,
    4. Ferrand M.,
    5. Durand G.,
    6. Le-Calvez Kelm F.,
    (2013) MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells. BMC Genomics 14, 139
    OpenUrlCrossRefPubMed
  28. ↵
    1. Cheng C.W.,
    2. Wang H.W.,
    3. Chang C.W.,
    4. Chu H.W.,
    5. Chen C.Y.,
    6. Yu J.C.,
    (2012) MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res. Treat. 134, 1081–1093
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Liu K.,
    2. Guo L.,
    3. Guo Y.,
    4. Zhou B.,
    5. Li T.,
    6. Yang H.,
    (2015) AEG-1 3′-untranslated region functions as a ceRNA in inducing epithelial-mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity. Eur. J. Cell Biol. 94, 22–31
    OpenUrlCrossRefPubMed
    1. Zhang N.,
    2. Wang X.,
    3. Huo Q.,
    4. Sun M.,
    5. Cai C.,
    6. Liu Z.,
    (2014) MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 33, 3119–3128
    OpenUrlCrossRefPubMed
  30. ↵
    1. He R.,
    2. Yang L.,
    3. Lin X.,
    4. Chen X.,
    5. Lin X.,
    6. Wei F.,
    (2015) MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1. Int. J. Clin. Exp. Pathol. 8, 15632–15641
    OpenUrl
  31. ↵
    1. Hua X.,
    2. Yu L.,
    3. Huang X.,
    4. Liao Z.,
    5. Xian Q.
    (2011) Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn. Pathol. 6, 111
    OpenUrlCrossRefPubMed
    1. Wikberg M.L.,
    2. Edin S.,
    3. Lundberg I.V.,
    4. Van Guelpen B.,
    5. Dahlin A.M.,
    6. Rutegard J.,
    (2013) High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 34, 1013–1020
    OpenUrlCrossRefPubMed
  32. ↵
    1. Cohen S.J.,
    2. Alpaugh R.K.,
    3. Palazzo I.,
    4. Meropol N.J.,
    5. Rogatko A.,
    6. Xu Z.,
    (2008) Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37, 154–158
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
Previous ArticleNext Article
Back to top

February 2018

Volume: 38 Issue: 1

Bioscience Reports: 38 (1)
  • Table of Contents
  • About the Cover
  • Index by author

Actions

Email

Thank you for your interest in spreading the word about Bioscience Reports.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP
(Your Name) has forwarded a page to you from Bioscience Reports
(Your Name) thought you would like to see this page from the Bioscience Reports web site.
Share
Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP
Peng Ruan, Zezhang Tao, Aili Tan
Bioscience Reports Feb 2018, 38 (1) BSR20171027; DOI: 10.1042/BSR20171027
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Facebook logo Mendeley logo
Citation Tools
Low expression of miR-30a-5p induced the proliferation and invasion of oral cancer via promoting the expression of FAP
Peng Ruan, Zezhang Tao, Aili Tan
Bioscience Reports Feb 2018, 38 (1) BSR20171027; DOI: 10.1042/BSR20171027

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print
Alerts

Please log in to add an alert for this article.

Request Permissions
Save to my folders

View Full PDF

 Open in Utopia Docs
  • Tweet Widget
  • Facebook Like

Jump To

  • Article
    • Abstract
    • Introduction
    • Materials and methods
    • Results
    • Discussion
    • Ethics approval and consent to participate
    • Consent for publication
    • Competing interests
    • Funding
    • Author contribution
    • References
  • Figures
  • Info & Metrics
  • PDF

Keywords

FAP
miR-30a-5p
oral cancer

Related Articles

Cited By...

  • Portland Press Homepage
  • Publish With Us
  • Advertising
  • Technical Support
  • Bioscience Reports
  • Biochemical Journal
  • Clinical Science
  • Neuronal Signaling
  • Essays in Biochemistry
  • Emerging Topics in Life Sciences
  • Biochemical Society Transactions
  • Biochemical Society Symposia
  • Cell Signalling Biology

Portland Press Limited
Charles Darwin House
12 Roger Street
London WC1N 2JU
Email: editorial@portlandpress.com

The Biochemical Society